Timothy Pigot - Aerovate Therapeutics VP Commercial
| AVTE Stock | USD 2.68 0.02 0.75% |
Insider
Timothy Pigot is VP Commercial of Aerovate Therapeutics
| Age | 53 |
| Address | 930 Winter Street, Waltham, MA, United States, 02451 |
| Phone | 617 443 2400 |
| Web | https://aerovatetx.com |
Aerovate Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4867) % which means that it has lost $0.4867 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8206) %, meaning that it created substantial loss on money invested by shareholders. Aerovate Therapeutics' management efficiency ratios could be used to measure how well Aerovate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.62. In addition to that, Return On Capital Employed is expected to decline to -0.78. At present, Aerovate Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting.Similar Executives
| Showing other executives | INSIDER Age | ||
| Carl Langren | Lumos Pharma | 69 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Lori CPA | Lumos Pharma | 40 | |
| Jeff York | Seres Therapeutics | N/A | |
| MBA MD | Eliem Therapeutics | 63 | |
| Hing Wong | HCW Biologics | 70 | |
| Bradley JD | Lumos Pharma | 45 | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Lisa Miller | Lumos Pharma | N/A | |
| Richard Hawkins | Lumos Pharma | 75 | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| Peter Rhode | HCW Biologics | 66 | |
| MD BA | Lumos Pharma | 69 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| David MBA | Seres Therapeutics | 63 | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.49 |
Aerovate Therapeutics Leadership Team
Elected by the shareholders, the Aerovate Therapeutics' board of directors comprises two types of representatives: Aerovate Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aerovate. The board's role is to monitor Aerovate Therapeutics' management team and ensure that shareholders' interests are well served. Aerovate Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aerovate Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Pigot, VP Commercial | ||
| Sanjeev Khindri, Executive Development | ||
| Benjamin Dake, President, Founder | ||
| Timothy MBA, CEO Director | ||
| Marinus Verwijs, Chief Officer | ||
| Stephen Yu, Senior Quality | ||
| BSc MD, Senior Development | ||
| Hunter MD, Chief Officer | ||
| MBA MR, Chief Officer | ||
| Susan Fischer, Executive Operations | ||
| Donna Dea, Head Affairs | ||
| George Eldridge, CFO Treasurer |
Aerovate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aerovate Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.49 | ||||
| Current Valuation | (11.38 M) | ||||
| Shares Outstanding | 28.87 M | ||||
| Shares Owned By Insiders | 0.02 % | ||||
| Shares Owned By Institutions | 99.98 % | ||||
| Number Of Shares Shorted | 549.75 K | ||||
| Price To Earning | 0.64 X | ||||
| Price To Book | 0.95 X | ||||
| EBITDA | (81.31 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.99) | Return On Assets (0.49) | Return On Equity (0.82) |
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.